AC Immune SA

NasdaqGM:ACIU Stock Report

Market Cap: US$198.9m

AC Immune Future Growth

Future criteria checks 2/6

AC Immune is forecast to grow earnings and revenue by 46.1% and 43.4% per annum respectively while EPS is expected to grow by 44.8% per annum.

Key information

46.1%

Earnings growth rate

44.80%

EPS growth rate

Biotechs earnings growth23.8%
Revenue growth rate43.4%
Future return on equityn/a
Analyst coverage

Low

Last updated04 May 2025

Recent future growth updates

Recent updates

AC Immune SA (NASDAQ:ACIU) Held Back By Insufficient Growth Even After Shares Climb 31%

Jun 11
AC Immune SA (NASDAQ:ACIU) Held Back By Insufficient Growth Even After Shares Climb 31%

Benign Growth For AC Immune SA (NASDAQ:ACIU) Underpins Stock's 26% Plummet

Apr 01
Benign Growth For AC Immune SA (NASDAQ:ACIU) Underpins Stock's 26% Plummet

AC Immune: Leader In Dementia Therapies, A Space Littered With Failures

Feb 19

AC Immune: Takeda Partnership Brings Funds To Drive Pipeline Forward

Jul 26

AC Immune (NASDAQ:ACIU) Is In A Strong Position To Grow Its Business

Jun 15
AC Immune (NASDAQ:ACIU) Is In A Strong Position To Grow Its Business

Shareholders Will Probably Hold Off On Increasing AC Immune SA's (NASDAQ:ACIU) CEO Compensation For The Time Being

Jun 15
Shareholders Will Probably Hold Off On Increasing AC Immune SA's (NASDAQ:ACIU) CEO Compensation For The Time Being

AC Immune SA's (NASDAQ:ACIU) 50% Share Price Surge Not Quite Adding Up

May 24
AC Immune SA's (NASDAQ:ACIU) 50% Share Price Surge Not Quite Adding Up

AC Immune SA (NASDAQ:ACIU) May Have Run Too Fast Too Soon With Recent 30% Price Plummet

Apr 05
AC Immune SA (NASDAQ:ACIU) May Have Run Too Fast Too Soon With Recent 30% Price Plummet

We Think AC Immune (NASDAQ:ACIU) Can Afford To Drive Business Growth

Mar 15
We Think AC Immune (NASDAQ:ACIU) Can Afford To Drive Business Growth

Companies Like AC Immune (NASDAQ:ACIU) Are In A Position To Invest In Growth

Oct 06
Companies Like AC Immune (NASDAQ:ACIU) Are In A Position To Invest In Growth

We Think AC Immune (NASDAQ:ACIU) Can Afford To Drive Business Growth

Jun 03
We Think AC Immune (NASDAQ:ACIU) Can Afford To Drive Business Growth

Will AC Immune (NASDAQ:ACIU) Spend Its Cash Wisely?

Nov 25
Will AC Immune (NASDAQ:ACIU) Spend Its Cash Wisely?

AC Immune Non-GAAP EPS of -$0.23 in-line

Jul 28

Here's Why We're Not Too Worried About AC Immune's (NASDAQ:ACIU) Cash Burn Situation

Jul 06
Here's Why We're Not Too Worried About AC Immune's (NASDAQ:ACIU) Cash Burn Situation

AC Immune (NASDAQ:ACIU) Is In A Good Position To Deliver On Growth Plans

Feb 03
AC Immune (NASDAQ:ACIU) Is In A Good Position To Deliver On Growth Plans

Is AC Immune (NASDAQ:ACIU) In A Good Position To Deliver On Growth Plans?

May 09
Is AC Immune (NASDAQ:ACIU) In A Good Position To Deliver On Growth Plans?

How Much Of AC Immune SA (NASDAQ:ACIU) Do Institutions Own?

Feb 28
How Much Of AC Immune SA (NASDAQ:ACIU) Do Institutions Own?

Analysts Just Made A Sizeable Upgrade To Their AC Immune SA (NASDAQ:ACIU) Forecasts

Jan 24
Analysts Just Made A Sizeable Upgrade To Their AC Immune SA (NASDAQ:ACIU) Forecasts

We're Hopeful That AC Immune (NASDAQ:ACIU) Will Use Its Cash Wisely

Jan 19
We're Hopeful That AC Immune (NASDAQ:ACIU) Will Use Its Cash Wisely

If You Had Bought AC Immune's (NASDAQ:ACIU) Shares Three Years Ago You Would Be Down 61%

Dec 15
If You Had Bought AC Immune's (NASDAQ:ACIU) Shares Three Years Ago You Would Be Down 61%

Need To Know: Analysts Are Much More Bullish On AC Immune SA (NASDAQ:ACIU) Revenues

Nov 19
Need To Know: Analysts Are Much More Bullish On AC Immune SA (NASDAQ:ACIU) Revenues

Earnings and Revenue Growth Forecasts

NasdaqGM:ACIU - Analysts future estimates and past financials data (CHF Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202768-232-803
12/31/202615-70-71-703
12/31/20254-77-78-613
3/31/202528-524546N/A
12/31/202427-516566N/A
9/30/202441-404344N/A
6/30/202415-614445N/A
3/31/202415-55-43-43N/A
12/31/202315-54-61-60N/A
9/30/20230-68-62-62N/A
6/30/20234-67-62-62N/A
3/31/20234-69-68-67N/A
12/31/20224-71-75-74N/A
9/30/20224-73-76-74N/A
6/30/2022N/A-76-77-75N/A
3/31/2022N/A-75-74-71N/A
12/31/2021N/A-73-68-66N/A
9/30/20211-71-70-67N/A
6/30/20212-74-71-68N/A
3/31/20213-71-69-67N/A
12/31/202015-62-61-60N/A
9/30/202015-62-54-53N/A
6/30/202047-25-22-20N/A
3/31/202048-26-22-20N/A
12/31/2019110455355N/A
9/30/2019111505556N/A
6/30/201980182627N/A
3/31/201981243435N/A
12/31/20187-51N/A-44N/A
9/30/201822-32N/A-26N/A
6/30/201821-27N/A-22N/A
3/31/201820-29N/A-24N/A
12/31/201720-26N/A-22N/A
9/30/20175-35N/A-35N/A
6/30/20176-36N/A-19N/A
3/31/201725-10N/A-10N/A
12/31/201623-7N/A-6N/A
9/30/201622-8N/A-4N/A
6/30/20164521N/A21N/A
3/31/20163917N/A16N/A
12/31/20153920N/A44N/A
9/30/20156546N/A45N/A
6/30/20154121N/A8N/A
3/31/20152810N/A7N/A
12/31/20143011N/A-18N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ACIU is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ACIU is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ACIU is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ACIU's revenue (43.4% per year) is forecast to grow faster than the US market (8.8% per year).

High Growth Revenue: ACIU's revenue (43.4% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if ACIU's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/06/30 08:34
End of Day Share Price 2025/06/30 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

AC Immune SA is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Thomas ShraderBTIG
Alethia YoungCredit Suisse
Andrew FeinH.C. Wainwright & Co.